Top Story

Word salad: What’s for dessert?

Word salad: What’s for dessert?
HemOnc Today, July 25, 2016
Derek Raghavan, MD, PhD

I enjoyed this year’s ASCO Annual Meeting.

The program committee has finally taken very seriously the entreaties from Lowell E. Schnipper, MD, and the gang, incorporating an assessment of value into programmatic content. I had the honor of acting as a value discussant for several strong presentations on the use of taxanes in the prostate cancer oral abstract session, and I was pleased to see that the presentations truly advanced our state of the art.


Adjunctive systemic therapy: A reasonable option for patients with muscle-invasive bladder cancer

HemOnc Today, July 25, 2016
Donald L. Trump, MD, FACP
It is with considerable trepidation that I undertake the assignment to comment on — nay, adjudicate — the “point” and “counter”…

How the making of it matters

HemOnc Today, July 25, 2016
Christine Cserti-Gazdewich, MD, FRCPC
We started with the idea that red cells are resilient. They live for 120 days, traversing capillaries and splenic meshes narrower than their unsprung diameters, while…
Cover Story

Immunotherapy, tumor profiling fill ‘gigantic knowledge gap’ in bladder cancer

HemOnc Today, July 25, 2016
The standard of care for patients with bladder cancer has remained largely unchanged for nearly 3 decades. The NCI estimates that 76,960 Americans will be diagnosed with…
In the Journals

Obesity may increase risk for pediatric VTE

HemOnc Today, July 25, 2016
Obesity may be a significant risk factor for venous thromboembolism among children, according to results of a single-institution study. Multiple risk factors for…
More News Headlines »

The Patient with Lymphadenopathy

No commercial support for this activity.

Castleman’s disease is a rare lymphoproliferative disorder that is characterized by enlargement of 1 (unicentric) or…
More »

VIDEO: James L. M. Ferrara, MD, DSc, reviews “long-standing problem” of GVHD after allogeneic HSCT

July 14, 2016
More »
2016 ASCO Annual Meeting

2016 ASCO Annual Meeting


NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today